- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01516866
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy (NaFl PET/CT)
14. november 2019 opdateret af: University of Wisconsin, Madison
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
The purpose of this research study is to evaluate a newer imaging technique, called 18F-Sodium Fluoride (NaF) positron emission tomography (PET).
NaF is a tracer (dye) that is very sensitive for changes in bone.
By using this tracer with positron emission tomography/computed tomography (PET/CT) imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study will look at how repeatable the NaF PET scans are before treatment.
Scans will also be performed after standard chemotherapy or hormone-directed treatment.
This will allow evaluation of how the NaF PET scans change with the chemotherapy or hormone-directed therapy.
In addition, NaF PET scans will be compared with standard computed tomography (CT) and bone scans, as well as prostate specific antigen (PSA).
This information could be used to develop better ways to measure prostate cancer bone lesions.
In turn, this could be used to better evaluate treatment effects of standard chemotherapy and other new drugs being developed to treat prostate cancer.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
58
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Maryland
-
Bethesda, Maryland, Forenede Stater, 20892
- National Cancer Institute
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Han
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Primary care clinic
Beskrivelse
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate
- Identifiable prostate cancer-related bone metastases on bone scan in the spine, pelvis or other bone
- Patients must be starting a microtubule directed chemotherapy regimen for metastatic castrate-resistant prostate cancer OR
- Patients must be starting a AR-directed regimen (e.g. Abiraterone, MDV-3100, TAK-700, etc) for treatment of metastatic castrate-resistant prostate
Exclusion Criteria:
- Concurrent treatment with any other agent that is being used with the expressed purpose of treating of prostate cancer outside of the planned treatment regimen
- Patients who have received radiotherapy less than 4 weeks prior to registration.
- Patients who have received prior Strontium-89, Samarium-153, or other radioisotope.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sodium fluoride F-18 (NaF).
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Cohort A: Microtubule directed chemotherapy treatment
Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment.
A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
|
Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B).
All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy.
A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning.
Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week).
Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
|
Cohort B: AR-directed therapy
Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks.
A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
|
Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B).
All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy.
A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning.
Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week).
Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
The repeatability of NaF PET/CT imaging for evaluating bone metastases in patients with metastatic castrate-resistant prostate cancer.
Tidsramme: 2 years
|
NaF PET/CT scan will be performed within 14 days prior to starting chemotherapy (antimicrotubule directed chemotherapy) or hormone-directed therapy (baseline #1).
A portion of subjects (up to 20 subjects at each site, 60 subjects total) will have a second NaF PET/CT scan performed (baseline #2) within 1-8 days of the initial scan to see if measurements repeated over a short period of time are similar.
|
2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Evaluate changes on NaF PET/CT images in response to chemotherapy (antimicrotubule directed chemotherapy) or androgen receptor (AR)-directed therapy.
Tidsramme: 2 years
|
All subjects will undergo NaF PET/CT scanning at baseline and again either 8 weeks after starting treatment with antimicrotubule chemotherapy based treatment (Cohort A) OR at both 6 weeks and 12 weeks after starting AR-directed treatment (Cohort B).
|
2 years
|
Prostate Specific Antigen (PSA) response
Tidsramme: 2 years
|
Results from the NaF PET/CT scans will be compared with PSA and bone scan and CT scan results.
|
2 years
|
Response Evaluation Criteria in Solid Tumors (RECIST) response
Tidsramme: 2 years
|
2 years
|
|
Radiographic progression free survival
Tidsramme: 2 years
|
2 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Robert Jeraj, Ph.D., University of Wisconsin, Madison
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. november 2011
Primær færdiggørelse (Faktiske)
1. september 2015
Studieafslutning (Faktiske)
1. januar 2018
Datoer for studieregistrering
Først indsendt
28. november 2011
Først indsendt, der opfyldte QC-kriterier
19. januar 2012
Først opslået (Skøn)
25. januar 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
18. november 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. november 2019
Sidst verificeret
1. april 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CO11811
- A534260 (Anden identifikator: UW Madison)
- SMPH\MEDICINE\HEM-ONC (Anden identifikator: UW Madison)
- 2011-0397 (Anden identifikator: Institutional Review Board)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
-
Imperial College LondonRekrutteringGlioblastoma Multiforme i hjernenDet Forenede Kongerige
-
Peking Union Medical College HospitalRekruttering
-
Stanford UniversityNational Institutes of Health (NIH)RekrutteringBiodistribution og farmakokinetik af positionsemissionstomografi (PET) Radiofarmaceutisk 18F C SNAT4Kræft | LungekræftForenede Stater
-
Washington University School of MedicineNational Cancer Institute (NCI)Afsluttet
-
Central Hospital, Nancy, FranceAfsluttet
-
University of ExeterRekrutteringParkinsons sygdom | Parkinsons sygdom | Neurodegenerative sygdomme | Positron emissionstomografi | Neurodegeneration | ParkinsonsDet Forenede Kongerige
-
University of ExeterRekrutteringParkinsons sygdom | Neurodegenerative sygdomme | Neurodegenerativ sygdom, arvelig | Parkinsons | Nervesystem lidelseDet Forenede Kongerige
-
University of ExeterRekrutteringParkinsons sygdom | Parkinsons sygdom | Neurodegenerative sygdomme | Positron emissionstomografi | Neurodegeneration | ParkinsonsDet Forenede Kongerige
-
Hospices Civils de LyonAfsluttet
-
University of AlbertaCanadian Urological Association Scholarship FoundationAktiv, ikke rekrutterende